Přínosy fixní kombinace inzulin glargin/lixisenatid u pacientů dlouhodobě léčených pro diabetes mellitus 2.typu ve světle nových dat

• Title in English: Advantages of fixed ratio combination of insulin glargin/lixisenatide fot the treatment of patients with long term diabetes type 2 in the light of new data
• Authors: ŽÁK Petr
• Year of publication: 2019
• Type: Article in Periodical
• Magazine / Source: Farmakoterapie
• MU Faculty or unit: Faculty of Medicine
• Web: https://www.farmakoterapie.cz/c6078/prinosy-fixni-kombinace-inzulin-glargin-lixisenatid-u-pacientu-dlouhodobe-lecenych-pro-diabetes-mellitus-2-typu-ve-svetle-novych-dat
• Keywords: lixisenatide glargine
• Description: Type 2 diabetes mellitus (DM2) results from multiple metabolic disorders: insulin resistance, [beta]-cell function impairment, increased hepatic glucose output, inadequate glucagon secretion, and impaired incretin effect. By the time DM2 fully develops, [beta]-cell counts are reduced by 40–65% and this decrease continues with the duration of the disease. Type 2 diabetes has a progressive character, intensification of treatment is therefore necessary not only to establish, but especially to maintain long-term acquired glycemic control. A more targeted approach to the pathophysiology of DM2, where combination therapy can effectively affect multiple individual metabolic disorders of a given disease at the same time, could have been a sought-after path over the years. The combination of basal insulin therapy and GLP-1 receptor agonist (GLP-1RA) appears to be a promising option. In the literature we find studies demonstrating the very good effect of fixed combination therapy with lixisenatide and insulin glargine (iGlarLixi) independent of the duration of DM2, with a low risk of hypoglycaemia in patients with a long duration of disease. The data obtained from randomized clinical trials are now confirmed by extensive meta-analyzes and we will expect the results of studies from real clinical practice in the near future.